Glucose Metabolism in Sickle Cell Disease

Diabetes Mellitus Clinical Trial

Official title:

Glucose Metabolism in Sickle Cell Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02922296
• Other study ID #: 2015-0366
• Status: Recruiting
• Start date: May 1, 2015
• Est. completion date: December 1, 2025

Study information

• Verified date: June 2023
• Source: University of Illinois at Chicago
• Contact: Victor Gordeuk, MD
• Phone: 312-996-5680
• Email: vgordeuk[@]uic.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of the study is to better understand how the body handles sugars glucose and fats, such as cholesterol and triglycerides in sickle cell disease, and what puts certain persons at risk to develop diabetes. This understanding may help us to find new treatments to control blood sugar and prevent diabetes in people with and without sickle cell disease (SCD).

In this research, DNA and RNA will be isolated from blood cells. DNA will be used to find genes that cause or protect from diabetes, high cholesterol and high triglyceride, and RNA will be used for studies designed to find out how genes are doing their job of eventually producing proteins.

Description:

Sickle cell disease (SCD) is due to homozygosity for a Glu6Val mutation in HBB (sickle cell anemia; hemoglobin SS) or to compound heterozygous forms like hemoglobin SC disease and hemoglobin S-β thalassemia. Past studies suggested a low prevalence of diabetes in patients with SCD.10 Improvements in treatment and care have increased the life span of patients. This, along with the wide availability of high calorie diets and increasing adiposity in SCD raises that possibility that the prevalence of diabetes is increasing in SCD. Our study is designed to characterize the changes in metabolism that occur in sickle cell disease and to identify clinical, genetic and genomic risk factors for the development of diabetes. Our hypothesis is that non-overweight subjects with SCD have relative protection from diabetes and metabolic syndrome, but that those individuals who do become overweight have a dramatic increase in the rates of diabetes and metabolic syndrome. Lean SCD subjects will not have simply a neutral, but an overtly anti-diabetic phenotype (e.g. better glucose tolerance and lower metabolic syndrome markers). The two main study aims are as follows; Aim 1. Define the metabolic status of adult SCD subjects according to normal or increased BMI.

Aim 2. Determine genetic and genomic predictors of overweight, metabolic syndrome and diabetes in SCD subjects.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 75
• Est. completion date: December 1, 2025
• Est. primary completion date: May 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Major sickling genotype (hemoglobin SS, Sbeta0-thalassemia, SOarab, SDpunjab)

• Age >35 years

• BMI <25 kg/m2 or >26 kg/m2

• Steady state, defined as >two weeks from a hospitalization for vaso-occlusive crisis, infection or surgery and not requiring immediate parenteral medication for pain control

• Fasting state (>8 hours since ingesting food or medication for diabetes)

Exclusion Criteria:

• Patients receiving insulin therapy

• Acute inflammatory or infectious illness or injury

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Diabetes Mellitus
• Sickle Cell Disease

Locations

Country	Name	City	State
United States	University of Illinois at Chicago	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
University of Illinois at Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Metabolic status of adult SCD subjects	The investigator will use the ATP III guidelines for definition of metabolic syndrome. A combination of any three of the following criteria will lead to the designation of metabolic syndrome: waist circumference >102 cm (men) or >88 cm (women); triglycerides =150 mg/dL; HDL cholesterol <40 mg/dL (men) or <50 mg/dL (women); blood pressure =130/=85 mg/dL (or recorded diagnosis of hypertension and use of antihypertensives); fasting glucose =110 mg/dL (or diagnosis of diabetes and use of anti-diabetic medications)	through study completion, approximately one year after subject participation
Secondary	Genetic and genomic predictors in SCD subjects	This will be accomplished by DNA linkage analysis and/or mutation analysis. In addition RNA will be isolated from from PBMCs and fractions of platelets, granulocytes and reticulocytes. The investigators will analyze the expression of transcripts to determine if alterations can explain the clinical observations.	through study completion, approximately one year after subject participation